Data gathered: November 7
Alternative Data for Sanofi
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
| Price | $51.26 |
| Target Price | Sign up |
| Volume | 3,010,000 |
| Market Cap | $133B |
| Year Range | $43.57 - $58.53 |
| Dividend Yield | 3.85% |
| PE Ratio | 27.1 |
| Analyst Rating | 67% buy |
| Industry | Drug Manufacturers |
In the news
 |
Janney Montgomery Scott LLC Sells 1,007 Shares of Sanofi (NASDAQ:SNY)November 6 - ETF Daily News |
|
Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $57.50November 5 - ETF Daily News |
|
Sanofi (NASDAQ:SNY) Position Trimmed by abrdn plcNovember 2 - ETF Daily News |
|
Wealth Enhancement Advisory Services LLC Has $3.05 Million Position in Sanofi (NASDAQ:SNY)November 2 - ETF Daily News |
|
First Trust Direct Indexing L.P. Raises Stock Position in Sanofi (NASDAQ:SNY)November 1 - ETF Daily News |
|
Sanofi (NASDAQ:SNY) Stock Rating Upgraded by StockNews.comOctober 31 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 21.2B | 6.85B | 14.4B | 2.25B | 5.43B | 0.930 |
| Q1 '24 | 11.1B | 3.44B | 7.68B | 1.13B | 2.87B | 0.970 |
| Q4 '23 | 22.9B | 9.06B | 13.8B | 1.97B | 7.77B | 0.890 |
| Q3 '23 | 12.7B | 3.84B | 8.86B | 2.53B | 4.16B | 2.770 |
| Q2 '23 | 10.7B | 3.27B | 7.41B | 1.44B | 2.83B | 0.950 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$157.88 0% | 50 |
 |
Eli Lilly and CompanyLLY |
$776.38 0% | 63 |
 |
PfizerPFE |
$27.36 0% | 40 |
 |
AstrazenecaAZN |
$63.85 0% | 64 |
 |
AbbVieABBV |
$201.2 0% | 56 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| John James |
Sep 2, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
Read more about Sanofi (SNY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Sanofi?
The Market Cap of Sanofi is $133B.
What is Sanofi's PE Ratio?
As of today, Sanofi's PE (Price to Earnings) ratio is 27.1.
What is the current stock price of Sanofi?
Currently, the price of one share of Sanofi stock is $51.26.
How can I analyze the SNY stock price chart for investment decisions?
The SNY stock price chart above provides a comprehensive visual representation of Sanofi's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sanofi shares. Our platform offers an up-to-date SNY stock price chart, along with technical data analysis and alternative data insights.
Does SNY offer dividends to its shareholders?
Yes, Sanofi (SNY) offers dividends to its shareholders, with a dividend yield of 3.85%. This dividend yield represents Sanofi's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Sanofi in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Sanofi?
Some of the similar stocks of Sanofi are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.